WO2015132341A1 - Pharmaceutical formulations of vildagliptin - Google Patents
Pharmaceutical formulations of vildagliptin Download PDFInfo
- Publication number
- WO2015132341A1 WO2015132341A1 PCT/EP2015/054631 EP2015054631W WO2015132341A1 WO 2015132341 A1 WO2015132341 A1 WO 2015132341A1 EP 2015054631 W EP2015054631 W EP 2015054631W WO 2015132341 A1 WO2015132341 A1 WO 2015132341A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- vildagliptin
- calcium phosphate
- pharmaceutical formulation
- dibasic calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent.
- a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent.
- the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).
- Vildagliptin is used for type 2 or non-insulin dependent diabetes. It increases the amount of insulin produced by the body. It also decreases the amount of glucagon which is produced by the body. Because of these effects, vildagliptin can help to control blood sugar levels in people with diabetes. Vildagliptin is used in combination with other medicines which help to control blood sugar levels.
- DPP-IV inhibitors work by blocking the action of DPP-IV, an enzyme which destroys the hormone incretin.
- DPP-IV an enzyme which destroys the hormone incretin.
- incretin hormones There are two types of incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1 ) and glucose-dependent insulinotropic peptide (GIP). These hormones are naturally produced by the body in response to food intake. Their function is to help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed.
- Vildagliptin works by binding to DPP-IV and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
- Vdagliptin is marketed under the trademark Galvus ® in 50 mg dosage forms by NOVARTIS. It is used against diabetes mellitus, but particularly in treating type 2 diabetes.
- Galvus ® includes lactose anhydrose, microcrystalline cellulose, sodium starch glycolate and magnesium stearate.
- microcrystalline cellulose is used as a diluent.
- dibasic calcium phosphate was used as a diluent to achieve improved compression and flowability in the formulation.
- diluent is used in a specific ratio in order to achieve desired release profile with desired tablet weight and desired flow during the process.
- Dibasic calcium phosphate has been chosen as a diluent to achieve high stability in the solid dosage form of vildagliptin.
- the present invention relates to a pharmaceutical formulation comprising;
- the ratio of vildagliptin to diluent is in the range of in the range of 0.04 to 0.24 (w/w).
- the ratio of vildagliptin to diluent is in the range of in the range of 0.04 to 0.24 (w/w), preferably 0.04 to 0.23 (w/w) and more preferably it is 0.1 to 0.21 (w/w).
- the patent application EP1841413A2 and EP2165703A3 disclose a direct compression of vildagliptin tablet formulation in a limited ratio of vildagliptin to diluent. It is often difficult to achieve desired dissolution profile in all the strengths.
- diluent is selected from the group comprising dibasic calcium phosphate, inorganic salts, sorbitol, tribasic calcium phosphate, dextrose, trehalose, microcrystalline cellulose, lactose, starch, sodium carbonate, sodium bicarbonate, calcium carbonate, dextrose, sucrose, maltodextrine, isomalt, xylitol, heavy magnesium carbonate or mixtures thereof, preferably it is dibasic calcium phosphate.
- the pharmaceutical formulation of this present invention was tested for its dissolution profile measured in 900ml_ of 0.1 N HCI at 50 rpm named as USP II (Paddle).
- diluent choice is important to provide adequate flow of powder mixture. It should be both compatible with active agent and other excipients and should not cause any stability problem.
- DPP-IV inhibitors are not very stable compounds.
- amine group containing DPP- IV inhibitors such as vildagliptin may react with many excipients or impurities of excipients.
- microcrystalline cellulose has been used as a diluent for vildagliptin tablet formulation.
- microcrystalline cellulose contains high humidity and it is known that vildagliptin is very sensitive to humidity.
- the stability assay has been performed by HPLC with isocratic mobile phase at a wavelength of UV 210 nm at 35 ⁇ 10 Q C of column temperature.
- the ratio of vildagliptin to dibasic calcium phosphate is in the range of 0.04 to 0.24 (w/w), preferably 0.04 to 0.23 (w/w) and more preferably it is 0.1 to 0.21 (w/w).
- Dibasic calcium phosphate has given good flow and compaction properties to the formulation due to its bulk density. It has been surprisingly found that the specific ratio of vildagliptin to dibasic calcium phosphate surprisingly provides low friability. In this embodiment, friability test has been performed with a drum with an internal diameter between 283-291 mm and a depth between 36-40 mm by rotating the drum 100 times, with 25 ⁇ 1 r/min rotation speed.
- the ratio of diluent to disintegrant is also crucial to achieve desired dissolution profile and optimum disintegration.
- the optimum ratio of dibasic calcium phosphate to croscarmellose sodium is in the range of 2 to 27 (w/w), preferably 5 to 20 (w/w) and more preferably it is 8 to 17 (w/w). It has been surprisingly found that when this ratio increases, excess amount of dibasic calcium phosphate causes an increase on disintegration, a decrease on dissolution properties of tablets and undesired stains on tablets. On the other side, a decrease in ratio of dibasic calcium phosphate to croscarmellose sodium causes destruction in the matrix and hence problems in dissolution.
- Suitable disintegrants may include, but not limited to croscarmellose sodium, carboxy methyl cellulose calcium, alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulphate, sodium carboxy methyl cellulose, polyvinylpyrrolidone, povidone, crospovidone, docusate sodium, guar gam, low-substitue HPC, HPMC, polyacrylin potasium, poloxomer, sodium alginate, sodium glysin carbonate, sodium lauryl sulphate., sodium starch glycolate, soy polysaccharide, gellan gum, xanthan gum, calcium silicate and mixtures thereof.
- Suitable binders may include but not limited to polyvinylpyrrolidone, sugars, glycose syrups, natural gums, guar gum, gelatins, pullulan, agar, alginate, sodium algynates, K-Karagen, glycyrrhizin, polymetacrylates, kollagen, agar, algynate, sodium alginate, hyaluronic acid, pectin, tragakanti gum, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate and their copolymers, cellulose derivatives such as hydroxypropyl methyl cellulose, carboxy methyl cellulose, methyl cellulose, microcrystalline cellulose, polyvinylalcohol, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, setostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage,
- Suitable lubricants may include but not limited to magnesium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin and mixtures thereof.
- Suitable glidants may include but not limited to colloidal silicon dioxide, aluminium silicate and mixtures thereof.
- Coating may also optionally be used for moisture protection. It can be selected from the group comprising polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat IR), polyvinyl alcohol or copolymers or mixtures thereof (Opadry AMB), Ethylcellulose Dispersions (Surelease), Kerry-HPC, polyethylene glycol, polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer(PVP-VA) and all kinds of OpadryTM, as well as pigments, dyes, titanium dioxide, iron oxide, talc and polymethylmetacrylate copolymers (Eudragit).
- these formulations have been designed, comprising the following: a. 14.0 - 16.0 % by weight of vildagliptin
- colloidal silicon dioxide e. 0.1 - 3.0 % by weight of colloidal silicon dioxide
- colloidal silicon dioxide e. 0.1 - 3.0 % by weight of colloidal silicon dioxide
- the production of the formulation is carried out as follows: Vildagliptin, colloidal silicone dioxide (Aerosil 200) and a part of dibasic calcium phosphate anhydride (Fujicalin SG) are sieved and mixed. Croscarmellose sodium, polyvinylpyrollidone (PVP 25) and other part of dibasic calcium phosphate are added to the mixture (Ac-Di-Sol) and mixed. The mixture is compacted in compactor and sieved. Magnesium stearate is sieved and added into obtained dry granules and mixed. Final mixture is pressed into tablets. Optionally, tablets are coated for moisture protection.
- the production of the formulation is carried out as follows: Vildagliptin, colloidal silicone dioxide (Aerosil 200) and a part of dibasic calcium phosphate anhydride (Fujicalin SG) are sieved and mixed. Croscarmellose sodium, polyvinylpyrollidone (PVP 25) and other part of dibasic calcium phosphate are added to the mixture (Ac-Di-Sol) and mixed. The mixture is compacted in compactor and sieved. Sodium stearyl fumarate is sieved and added into obtained dried granules and mixed. Final mixture is pressed into tablets. Optionally, tablets are coated for moisture protection.
- Friability test has been performed by rotating the drum 100 times, with 25 ⁇ 1 r/min rotation speed.
- the pharmaceutical formulation of this present invention was tested for its dissolution profile measured in 900ml_ of 0.1 N HCI at 50 rpm named as USP II (Paddle).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).
Description
DESCRIPTION
PHARMACEUTICAL FORMULATIONS OF VILDAGLIPTIN Field of Invention
The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).
Background of Invention
Vildagliptin is used for type 2 or non-insulin dependent diabetes. It increases the amount of insulin produced by the body. It also decreases the amount of glucagon which is produced by the body. Because of these effects, vildagliptin can help to control blood sugar levels in people with diabetes. Vildagliptin is used in combination with other medicines which help to control blood sugar levels.
DPP-IV inhibitors work by blocking the action of DPP-IV, an enzyme which destroys the hormone incretin. There are two types of incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1 ) and glucose-dependent insulinotropic peptide (GIP). These hormones are naturally produced by the body in response to food intake. Their function is to help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. Vildagliptin works by binding to DPP-IV and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
Formula I
Its chemical name is (S)-{[(3-hydroxyadamantan-1 -yl)amino]acetyl}pyrrolidine-2-carbonitril and its chemical structure is shown in the Formula I.
Vildagliptin is marketed under the trademark Galvus® in 50 mg dosage forms by NOVARTIS. It is used against diabetes mellitus, but particularly in treating type 2 diabetes. Galvus® includes lactose anhydrose, microcrystalline cellulose, sodium starch glycolate and magnesium stearate.
In currently commercially available dose of vildagliptin formulation, microcrystalline cellulose is used as a diluent. In contrast, in this present invention, dibasic calcium phosphate was used as a diluent to achieve improved compression and flowability in the formulation.
There are various patents and applications available in the patent literature in relation to vildagliptin formulations. In the patent application EP1841413A2 and EP2165703A3, direct compression is used to develop tablet formulation of DPP-IV inhibitor compounds, especially vildagliptin or an acid addition salt thereof.
It is known that DPP-IV inhibitors with primary or secondary amino group show incompatibilities, degradation problems or extraction problems with some excipients especially excipients that have acidic properties. Vildagliptin has also a secondary amino group on its chemical structure. In solid dosage forms, it may react with many excipients or impurities of excipients, although vildagliptin itself is very stable.
In this invention, diluent is used in a specific ratio in order to achieve desired release profile with desired tablet weight and desired flow during the process. Dibasic calcium phosphate has been chosen as a diluent to achieve high stability in the solid dosage form of vildagliptin.
Description of the invention The present invention relates to a pharmaceutical formulation comprising;
a) vildagliptin or pharmaceutically acceptable salt thereof, and
b) a diluent,
wherein the ratio of vildagliptin to diluent is in the range of in the range of 0.04 to 0.24 (w/w). In one embodiment, in the formulation of this present invention, the ratio of vildagliptin to diluent is in the range of in the range of 0.04 to 0.24 (w/w), preferably 0.04 to 0.23 (w/w) and more preferably it is 0.1 to 0.21 (w/w).
In prior art, the patent application EP1841413A2 and EP2165703A3 disclose a direct compression of vildagliptin tablet formulation in a limited ratio of vildagliptin to diluent. It is often difficult to achieve desired dissolution profile in all the strengths. To overcome such problem it is always necessary to optimize size and surface area of a tablet. In comparison to prior art, in this present invention, it has been found that with a lower ratio of vildagliptin to diluent has given desired dissolution profile. With this ratio, more uniform dissolution profile has also been achieved due to an increase in weight and surface area of the tablet. In this embodiment, diluent is selected from the group comprising dibasic calcium phosphate, inorganic salts, sorbitol, tribasic calcium phosphate, dextrose, trehalose, microcrystalline cellulose, lactose, starch, sodium carbonate, sodium bicarbonate, calcium carbonate, dextrose, sucrose, maltodextrine, isomalt, xylitol, heavy magnesium carbonate or mixtures thereof, preferably it is dibasic calcium phosphate.
The pharmaceutical formulation of this present invention was tested for its dissolution profile measured in 900ml_ of 0.1 N HCI at 50 rpm named as USP II (Paddle).
In direct compression for the tablet development process, diluent choice is important to provide adequate flow of powder mixture. It should be both compatible with active agent and other excipients and should not cause any stability problem. In general, DPP-IV inhibitors are not very stable compounds. Especially, in solid dosage forms, amine group containing DPP- IV inhibitors such as vildagliptin may react with many excipients or impurities of excipients. In prior art, microcrystalline cellulose has been used as a diluent for vildagliptin tablet formulation. However, microcrystalline cellulose contains high humidity and it is known that vildagliptin is very sensitive to humidity. In this invention, to ensure flowability of formulation dibasic calcium phosphate has been used and it has been surprisingly found that it provides high stability. The stability assay has been performed by HPLC with isocratic mobile phase at a wavelength of UV 210 nm at 35 ± 10 QC of column temperature.
In one embodiment, the ratio of vildagliptin to dibasic calcium phosphate is in the range of 0.04 to 0.24 (w/w), preferably 0.04 to 0.23 (w/w) and more preferably it is 0.1 to 0.21 (w/w).
Dibasic calcium phosphate has given good flow and compaction properties to the formulation due to its bulk density. It has been surprisingly found that the specific ratio of vildagliptin to dibasic calcium phosphate surprisingly provides low friability. In this embodiment, friability test has been performed with a drum with an internal diameter between 283-291 mm and a depth between 36-40 mm by rotating the drum 100 times, with 25 ± 1 r/min rotation speed.
Furthermore, by using this specific ratio of vildagliptin to dibasic calcium phosphate, tablet compaction speed has been increased without any problem such as content uniformity. It has been observed that the compaction speed is between 100.000 tb/h. to 40.000 tb/h.
In addition, in a tablet formulation the ratio of diluent to disintegrant is also crucial to achieve desired dissolution profile and optimum disintegration. In this invention, it has been found that the optimum ratio of dibasic calcium phosphate to croscarmellose sodium is in the range of 2 to 27 (w/w), preferably 5 to 20 (w/w) and more preferably it is 8 to 17 (w/w). It has been surprisingly found that when this ratio increases, excess amount of dibasic calcium phosphate causes an increase on disintegration, a decrease on dissolution properties of tablets and undesired stains on tablets. On the other side, a decrease in ratio of dibasic calcium phosphate to croscarmellose sodium causes destruction in the matrix and hence problems in dissolution. Therefore, in this invention an optimum ratio of dibasic calcium phosphate to croscarmellose sodium has been provided in order to achieve desired matrix and dissolution without any physical problems on tablets. Suitable disintegrants may include, but not limited to croscarmellose sodium, carboxy methyl cellulose calcium, alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulphate, sodium carboxy methyl cellulose, polyvinylpyrrolidone, povidone, crospovidone, docusate sodium, guar gam, low-substitue HPC, HPMC, polyacrylin potasium, poloxomer, sodium alginate, sodium glysin carbonate, sodium lauryl sulphate., sodium starch glycolate, soy polysaccharide, gellan gum, xanthan gum, calcium silicate and mixtures thereof.
Suitable binders may include but not limited to polyvinylpyrrolidone, sugars, glycose syrups, natural gums, guar gum, gelatins, pullulan, agar, alginate, sodium algynates, K-Karagen, glycyrrhizin, polymetacrylates, kollagen, agar, algynate, sodium alginate, hyaluronic acid, pectin, tragakanti gum, carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinyl acetate and their copolymers, cellulose derivatives such as hydroxypropyl methyl
cellulose, carboxy methyl cellulose, methyl cellulose, microcrystalline cellulose, polyvinylalcohol, carrageenan, carbomer, poloxamer, polyacrylamide, aluminum hydroxide, benthonite, laponite, setostearyl alcohol, polyoxyethylene-alkyl ethers, acacia mucilage, polydextrose, polyethylene oxide, xylitol, sucrose stearate, and mixtures thereof.
Suitable lubricants may include but not limited to magnesium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin and mixtures thereof.
Suitable glidants may include but not limited to colloidal silicon dioxide, aluminium silicate and mixtures thereof.
Coating may also optionally be used for moisture protection. It can be selected from the group comprising polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat IR), polyvinyl alcohol or copolymers or mixtures thereof (Opadry AMB), Ethylcellulose Dispersions (Surelease), Kerry-HPC, polyethylene glycol, polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer(PVP-VA) and all kinds of OpadryTM, as well as pigments, dyes, titanium dioxide, iron oxide, talc and polymethylmetacrylate copolymers (Eudragit).
In this present invention, to achieve desired dissolution and stability with an improved process, these formulations have been designed, comprising the following: a. 14.0 - 16.0 % by weight of vildagliptin
b. 70.0 - 80.0 % by weight of dibasic calcium phosphate
c. 3.0 - 25.0 % by weight of croscarmellose sodium
d. 0.1 - 25.0 % by weight of polyvinylpyrollidone
e. 0.1 - 3.0 % by weight of colloidal silicon dioxide
f. 0.01 - 5.0 % by weight of magnesium stearate
g. Optionally, coating
and,
a. 14.0 - 16.0 % by weight of vildagliptin
b. 70.0 - 80.0 % by weight of dibasic calcium phosphate
c. 3.0 - 25.0 % by weight of croscarmellose sodium
d. 0.1 - 25.0 % by weight of polyvinylpyrollidone
e. 0.1 - 3.0 % by weight of colloidal silicon dioxide
f. 0.01 - 2.0 % by weight of sodium stearyl fumarate
g. Optionally, coating
Example 1 : Compaction
The production of the formulation is carried out as follows: Vildagliptin, colloidal silicone dioxide (Aerosil 200) and a part of dibasic calcium phosphate anhydride (Fujicalin SG) are sieved and mixed. Croscarmellose sodium, polyvinylpyrollidone (PVP 25) and other part of dibasic calcium phosphate are added to the mixture (Ac-Di-Sol) and mixed. The mixture is compacted in compactor and sieved. Magnesium stearate is sieved and added into obtained dry granules and mixed. Final mixture is pressed into tablets. Optionally, tablets are coated for moisture protection.
Example 2: Direct Compression
The production of the formulation is carried out as follows: Vildagliptin, colloidal silicone dioxide (Aerosil 200) and a part of dibasic calcium phosphate anhydride (Fujicalin SG) are sieved and mixed. Croscarmellose sodium, polyvinylpyrollidone (PVP 25) and other part of dibasic calcium phosphate are added to the mixture (Ac-Di-Sol) and mixed. The mixture is compacted in compactor and sieved. Sodium stearyl fumarate is sieved and added into
obtained dried granules and mixed. Final mixture is pressed into tablets. Optionally, tablets are coated for moisture protection.
Table 1 : friability test
Friability test has been performed by rotating the drum 100 times, with 25 ± 1 r/min rotation speed.
Table 2: dissolution profile
The pharmaceutical formulation of this present invention was tested for its dissolution profile measured in 900ml_ of 0.1 N HCI at 50 rpm named as USP II (Paddle).
Claims
1 . A pharmaceutical formulation comprising;
a) vildagliptin or pharmaceutically acceptable salt thereof, and
b) a diluent,
wherein the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).
2. The pharmaceutical formulation according to claim 1 , wherein the ratio of vildagliptin to diluent is in the range of in the range of 0.04 to 0.24 (w/w), preferably 0.04 to 0.23 (w/w) and more preferably it is 0.1 to 0.21 (w/w).
3. The pharmaceutical formulation according to claim 1 , wherein the diluent is selected inorganic salts, sorbitol, tribasic calcium phosphate, dextrose, trehalose, microcrystalline cellulose, lactose, starch, sodium carbonate, sodium bicarbonate, calcium carbonate, dextrose, sucrose, maltodextrine, isomalt, xylitol, heavy magnesium carbonate or mixtures thereof, preferably it is dibasic calcium phosphate.
4. The pharmaceutical formulation according to 1 or 2, wherein the ratio of vildagliptin to dibasic calcium phosphate is in the range of 0.04 to 0.24 (w/w), preferably 0.04 to 0.23 (w/w) and more preferably it is 0.1 to 0.21 (w/w).
5. The pharmaceutical formulation according to any of the preceding claims, wherein the ratio of dibasic calcium phosphate to croscarmellose sodium rate is in the range of 2 to 27 (w/w), preferably 5 to 20 (w/w) and more preferably it is 8 to 17 (w/w).
6. The pharmaceutical formulation according to any preceding claim comprising;
a. 14.0 - 16.0 % by weight of vildagliptin
b. 70.0 - 80.0 % by weight of dibasic calcium phosphate
c. 3.0 - 25.0 % by weight of croscarmellose sodium
d. 0.1 - 25.0 % by weight of polyvinylpyrollidone
e. 0.1 - 3.0 % by weight of colloidal silicon dioxide
f. 0.01 - 5.0 % by weight of magnesium stearate
g. Optionally, coating
7. The pharmaceutical formulation according to any preceding claim comprising;
a. 14.0 - 16.0 % by weight of vildagliptin
b. 70.0 - 80.0 % by weight of dibasic calcium phosphate
c. 3.0 - 25.0 % by weight of croscarmellose sodium
d. 0.1 - 25.0 % by weight of polyvinylpyroliidone
e. 0.1 - 3.0 % by weight of coiioidai silicon dioxide
f. 0.01 - 2.0 % by weight of sodium stearyl fumarate
g. Optionally, coating
8. The pharmaceutical formulation according to any preceding claim comprising; a. 15.6 % by weight of vildagliptin
b. 74.5 % by weight of dibasic calcium phosphate
c. 5.0 % by weight of croscarmellose sodium
d. 3.1 % by weight of polyvinylpyroliidone
e. 0.6 % by weight of colloidal silicon dioxide
f. 1 .1 % by weight of magnesium stearate
g. Optionally, coating
9. The pharmaceutical formulation according to any preceding claim comprising; a. 15.6 % by weight of vildagliptin
b. 74.5 % by weight of dibasic calcium phosphate
c. 5.0 % by weight of croscarmellose sodium
d. 3.1 % by weight of polyvinylpyroliidone
e. 0.6 % by weight of colloidal silicon dioxide
f. 1 .1 % by weight of sodium stearyl fumarate
g. Optionally, coating
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/123,818 US9795592B2 (en) | 2014-03-06 | 2015-03-05 | Pharmaceutical formulations of vildagliptin |
| EA201691792A EA030758B1 (en) | 2014-03-06 | 2015-03-05 | PHARMACEUTICAL COMPOSITIONS BASED ON VILDAGLIPTINA |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2014/02685A TR201402685A1 (en) | 2014-03-06 | 2014-03-06 | Pharmaceutical formulations of vildagliptin |
| TR2014/02685 | 2014-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015132341A1 true WO2015132341A1 (en) | 2015-09-11 |
Family
ID=52706141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2015/054631 Ceased WO2015132341A1 (en) | 2014-03-06 | 2015-03-05 | Pharmaceutical formulations of vildagliptin |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9795592B2 (en) |
| EP (1) | EP2915527A1 (en) |
| EA (1) | EA030758B1 (en) |
| GE (2) | GEAP201914292A (en) |
| TR (1) | TR201402685A1 (en) |
| WO (1) | WO2015132341A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019182756A (en) * | 2018-04-03 | 2019-10-24 | 大原薬品工業株式会社 | Solid preparation containing vildagliptin |
| WO2021136507A1 (en) * | 2019-12-31 | 2021-07-08 | 石药集团中奇制药技术（石家庄）有限公司 | Pharmaceutical composition of dipeptidyl peptidase-4 inhibitor, and preparation method therefor and use thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3740282B1 (en) | 2018-01-17 | 2025-03-26 | University of Connecticut | Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease |
| CN111821271A (en) * | 2020-08-26 | 2020-10-27 | 杭州新诺华医药有限公司 | Vildagliptin composition and preparation method thereof |
| CN115308325B (en) * | 2022-08-03 | 2023-07-28 | 海南通用三洋药业有限公司 | Method for detecting residual solvent of vildagliptin |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1841413A2 (en) | 2005-01-18 | 2007-10-10 | Novartis AG | Direct compression formulation and process |
| EP2165703A2 (en) | 2004-01-20 | 2010-03-24 | Novartis Pharma AG. | Direct compression formulation and process |
| EP2578208A1 (en) * | 2011-10-06 | 2013-04-10 | Sanovel Ilac Sanayi ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
| WO2013062902A2 (en) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234105A (en) * | 2008-01-09 | 2008-08-06 | 北京润德康医药技术有限公司 | Pharmaceutical composition containing diabetosan and vildagliptin and preparation thereof |
| WO2011012322A2 (en) * | 2009-07-31 | 2011-02-03 | Krka, D.D., Novo Mesto | Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms |
| CA2777231A1 (en) * | 2009-10-23 | 2011-04-28 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
-
2014
- 2014-03-06 TR TR2014/02685A patent/TR201402685A1/en unknown
-
2015
- 2015-03-05 EP EP15157759.0A patent/EP2915527A1/en not_active Withdrawn
- 2015-03-05 GE GEAP201914292A patent/GEAP201914292A/en unknown
- 2015-03-05 US US15/123,818 patent/US9795592B2/en not_active Expired - Fee Related
- 2015-03-05 EA EA201691792A patent/EA030758B1/en not_active IP Right Cessation
- 2015-03-05 GE GEAP201514292A patent/GEP20196977B/en unknown
- 2015-03-05 WO PCT/EP2015/054631 patent/WO2015132341A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2165703A2 (en) | 2004-01-20 | 2010-03-24 | Novartis Pharma AG. | Direct compression formulation and process |
| US20120294939A1 (en) * | 2004-01-20 | 2012-11-22 | James Kowalski | Direct compression formulation and process |
| EP1841413A2 (en) | 2005-01-18 | 2007-10-10 | Novartis AG | Direct compression formulation and process |
| EP2578208A1 (en) * | 2011-10-06 | 2013-04-10 | Sanovel Ilac Sanayi ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
| WO2013062902A2 (en) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019182756A (en) * | 2018-04-03 | 2019-10-24 | 大原薬品工業株式会社 | Solid preparation containing vildagliptin |
| WO2021136507A1 (en) * | 2019-12-31 | 2021-07-08 | 石药集团中奇制药技术（石家庄）有限公司 | Pharmaceutical composition of dipeptidyl peptidase-4 inhibitor, and preparation method therefor and use thereof |
| CN114641277A (en) * | 2019-12-31 | 2022-06-17 | 石药集团中奇制药技术（石家庄）有限公司 | Pharmaceutical composition of dipeptidyl peptidase 4 inhibitor and preparation method and application thereof |
| CN114641277B (en) * | 2019-12-31 | 2023-06-13 | 石药集团中奇制药技术（石家庄）有限公司 | A pharmaceutical composition of dipeptidyl peptidase 4 inhibitor, its preparation method and application |
| CN116509844A (en) * | 2019-12-31 | 2023-08-01 | 石药集团中奇制药技术（石家庄）有限公司 | Pharmaceutical composition of dipeptidyl peptidase 4 inhibitor and preparation method and application thereof |
| CN116509844B (en) * | 2019-12-31 | 2024-06-04 | 石药集团中奇制药技术（石家庄）有限公司 | Pharmaceutical composition of dipeptidyl peptidase 4 inhibitor and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2915527A1 (en) | 2015-09-09 |
| US9795592B2 (en) | 2017-10-24 |
| TR201402685A1 (en) | 2015-09-21 |
| GEP20196977B (en) | 2019-06-10 |
| US20170014379A1 (en) | 2017-01-19 |
| EA201691792A1 (en) | 2016-12-30 |
| EA030758B1 (en) | 2018-09-28 |
| GEAP201914292A (en) | 2019-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110548147B (en) | Pharmaceutical composition containing glucokinase activator and DPP-IV inhibitor and preparation method and application thereof | |
| BR112012028035A2 (en) | dosage form and immediate release formulation, and use of the same | |
| US9795592B2 (en) | Pharmaceutical formulations of vildagliptin | |
| CA2611114A1 (en) | An entacapone-containing oral dosage form | |
| US20070104785A1 (en) | Tablets of linezolid form iii and processes for their preparation | |
| EP2468361B1 (en) | Vildagliptin Formulations | |
| EP2848242A1 (en) | Orally disintegrating formulations of Linagliptin | |
| EP3801539B1 (en) | Solid oral pharmaceutical compositions of linagliptin | |
| JP2017523149A (en) | Edoxaban pharmaceutical composition | |
| EP2722034B1 (en) | Oral pharmaceutical formulations comprising dabigatran | |
| EP4019003A1 (en) | Pharmaceutical formulations of linagliptin | |
| EP3648745B1 (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
| KR101485421B1 (en) | Controlled-release Oral Drug Preparations and it's Manufacturing Process Containing Itopride Hydrochloride | |
| WO2019203755A2 (en) | A solid oral dosage form comprising linagliptin | |
| JP7585043B2 (en) | Pharmaceutical compositions containing lenalidomide | |
| EP3338767A1 (en) | Capsule compositions comprising donepezil and memantine | |
| EP3318279A1 (en) | Solid oral pharmaceutical compositions of lurasidone hydrochloride | |
| WO2018122262A1 (en) | Bilayer tablet formulations of dabigatran etexilate | |
| US20090298944A1 (en) | Pharmaceutical composition | |
| US20060099262A1 (en) | Methods and formulations for making controlled release oral dosage form | |
| WO2014096983A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| US20060099261A1 (en) | Methods and formulations for making controlled release oral dosage form | |
| WO2022173406A1 (en) | A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof | |
| TWI388336B (en) | Pharmaceutical composition for parkinson's disease | |
| WO2013100876A1 (en) | Risperidone formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15711440 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 15123818 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: A201610126 Country of ref document: UA Ref document number: 14292 Country of ref document: GE Ref document number: 201691792 Country of ref document: EA |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15711440 Country of ref document: EP Kind code of ref document: A1 |